107 related articles for article (PubMed ID: 10192639)
1. Assessing individual patients for cognitive benefits from acetylcholinesterase inhibitors.
Sands LP; Katz I; Schneider L
Alzheimer Dis Assoc Disord; 1999 Jan; 13(1):26-33. PubMed ID: 10192639
[TBL] [Abstract][Full Text] [Related]
2. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.
Rogers SL; Doody RS; Mohs RC; Friedhoff LT
Arch Intern Med; 1998 May; 158(9):1021-31. PubMed ID: 9588436
[TBL] [Abstract][Full Text] [Related]
3. Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration.
Qizilbash N; Whitehead A; Higgins J; Wilcock G; Schneider L; Farlow M
JAMA; 1998 Nov; 280(20):1777-82. PubMed ID: 9842955
[TBL] [Abstract][Full Text] [Related]
4. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of a loading-dose regimen versus a no-loading-dose regimen of metrifonate in the symptomatic treatment of Alzheimer's disease: a randomized, double-masked, placebo-controlled trial. Metrifonate Study Group.
Jann MW; Cyrus PA; Eisner LS; Margolin DI; Griffin T; Gulanski B
Clin Ther; 1999 Jan; 21(1):88-102. PubMed ID: 10090427
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of cholinergic treatment in demented patients by P300 evoked related potentials.
Werber AE; Klein C; Rabey JM
Neurol Neurochir Pol; 2001; 35 Suppl 3():37-43. PubMed ID: 12001652
[TBL] [Abstract][Full Text] [Related]
7. Acetylcholinesterase inhibition in dementia with Lewy bodies: results of a prospective pilot trial.
Querfurth HW; Allam GJ; Geffroy MA; Schiff HB; Kaplan RF
Dement Geriatr Cogn Disord; 2000; 11(6):314-21. PubMed ID: 11044776
[TBL] [Abstract][Full Text] [Related]
8. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial.
De Jesus Moreno Moreno M
Clin Ther; 2003 Jan; 25(1):178-93. PubMed ID: 12637119
[TBL] [Abstract][Full Text] [Related]
9. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease.
Doody RS; Dunn JK; Clark CM; Farlow M; Foster NL; Liao T; Gonzales N; Lai E; Massman P
Dement Geriatr Cogn Disord; 2001; 12(4):295-300. PubMed ID: 11351141
[TBL] [Abstract][Full Text] [Related]
10. The Alzheimer's Disease Assessment Scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials.
Doraiswamy PM; Bieber F; Kaiser L; Krishnan KR; Reuning-Scherer J; Gulanski B
Neurology; 1997 Jun; 48(6):1511-7. PubMed ID: 9191757
[TBL] [Abstract][Full Text] [Related]
11. One-year treatment of Alzheimer's disease with acetylcholinesterase inhibitors: improvement on ADAS-cog and TMT A, no change or worsening on other tests.
Borkowska A; Ziolkowska-Kochan M; Rybakowski JK
Hum Psychopharmacol; 2005 Aug; 20(6):409-14. PubMed ID: 15991260
[TBL] [Abstract][Full Text] [Related]
12. The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group.
Raskind MA; Cyrus PA; Ruzicka BB; Gulanski BI
J Clin Psychiatry; 1999 May; 60(5):318-25. PubMed ID: 10362441
[TBL] [Abstract][Full Text] [Related]
13. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.
Morris JC; Cyrus PA; Orazem J; Mas J; Bieber F; Ruzicka BB; Gulanski B
Neurology; 1998 May; 50(5):1222-30. PubMed ID: 9595967
[TBL] [Abstract][Full Text] [Related]
14. Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer disease.
Raskind MA; Sadowsky CH; Sigmund WR; Beitler PJ; Auster SB
Arch Neurol; 1997 Jul; 54(7):836-40. PubMed ID: 9236571
[TBL] [Abstract][Full Text] [Related]
15. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group.
Knapp MJ; Knopman DS; Solomon PR; Pendlebury WW; Davis CS; Gracon SI
JAMA; 1994 Apr; 271(13):985-91. PubMed ID: 8139083
[TBL] [Abstract][Full Text] [Related]
16. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
[TBL] [Abstract][Full Text] [Related]
17. Clinical meaningfulness of Alzheimer's Disease Assessment Scale-Cognitive subscale change in relation to goal attainment in patients on cholinesterase inhibitors.
Rockwood K; Howlett SE; Hoffman D; Schindler R; Mitnitski A
Alzheimers Dement; 2017 Oct; 13(10):1098-1106. PubMed ID: 28341540
[TBL] [Abstract][Full Text] [Related]
18. Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.
Wattmo C; Minthon L; Wallin ÅK
Alzheimers Res Ther; 2016 Feb; 8():7. PubMed ID: 26883213
[TBL] [Abstract][Full Text] [Related]
19. Key methodological features of randomized controlled trials of Alzheimer's disease therapy. Minimal clinically important difference, sample size and trial duration.
Burback D; Molnar FJ; St John P; Man-Son-Hing M
Dement Geriatr Cogn Disord; 1999; 10(6):534-40. PubMed ID: 10559571
[TBL] [Abstract][Full Text] [Related]
20. Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients.
Visser PJ; Scheltens P; Pelgrim E; Verhey FR;
Dement Geriatr Cogn Disord; 2005; 19(2-3):126-33. PubMed ID: 15627759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
